• one measure of the skeletal component of the systemic disorder of CKD-MBD that is quantifiable by histomorphometry of bone biopsy. The guidelines themselves focussed on three key domains relating to:
(1) diagnosis of CKD-MBD with respect to biochemical abnormalities, bone and vascular calcification, 2009 saw the publication of the clinical practice guidelines from Kidney Disease Improving Global Outcomes (KDIGO) relating to diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [1] .
KDIGO has utilised a grading system for clinical practice recommendations with the strength of recommendation being graded as level 1 or level 2, with level 1 being a 'we recommend ...' statement implying most patients should receive this action whilst level 2 is a 'suggestion' recognising that management decisions may vary in different clinical contexts. Each recommendation was further graded from A to D by the quality of evidence underpinning them, with grade A referring to a high quality of evidence whilst grade D recognised a 'very low' evidence base.
KDIGO defined CKD-MBD as systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:
• abnormalities of calcium, phosphate, parathyroid hormone (PTH) or vitamin D metabolism, • abnormalities in bone turnover, mineralisation, volume, linear growth or strength, • vascular or other soft-tissue calcification.
To avoid confusion renal osteodystrophy was defined as:
• an alteration of bone morphology in patients with CKD, Key aspects of the guidelines are summarised in tables 1-3 . The guidelines represent an impressive and exhaustive summary of the true evidence base underlying clinical practice and have identified key gaps in knowledge. In general they are much less prescriptive than previous guidelines in this area and it is striking that KDIGO issued only 39 guideline statements in contrast to the K-DOQI guidelines [2] , which issued 104 guideline statements of which only 16 were evidence-based. This weak evidence base is highlighted by the fact that there were absolutely no 'A' quality studies related to patient outcomes such as mortality, hospitalisation, quality of life or clinical cardiovascular disease. To this end the group prioritised areas for future research focussing on patientcentred outcomes such as risk stratification for clinical outcomes determining the value of protocol-driven interventions for phosphate and PTH in improving hard clinical endpoints. Whilst some have complained that this is a weak and vague document leaving individual clinicians with the freedom to do almost anything (or even nothing), numerous studies remind us of the fundamental flaw and danger of basing clinical guidelines on observational data [3] . 
